The potential of GLP-1 receptor agonists to improve glycemic control, promote weight reduction, and enhance musculoskeletal health presents a promising avenue for reducing the burden of obesity and T2DM in orthopedic practice. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.